New hope for lung cancer patients whose immunotherapy stopped working

NCT ID NCT07412262

First seen Feb 20, 2026 · Last updated May 08, 2026 · Updated 15 times

Summary

This study tests a combination of two drugs, chidamide and ivonescimab, in 32 adults with advanced non-small cell lung cancer that has stopped responding to immunotherapy and has high levels of a protein called YAP. The goal is to see if the combo can shrink tumors or delay cancer growth. Participants will receive the drugs and be monitored for side effects and disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

    Guangzhou, Guangdong, 510080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-••••

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.